Finemedix

At a glance

Finemedix filed 25 disclosures in the last 12 months, including 3 5% holder, 2 buyback, 1 contract and 1 issuance. The most recent key filing was on Jul 22.

Revenue for 2025 was ₩9.5B, down 4.4% on 2024. It made an operating loss of ₩2.6B. Debt was 34% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩6.3B and operating profit of ₩39M.

The 2025 annual report lists 77 employees with an average tenure of 5 years and average pay of ₩45.6M, #1631 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩131M each on average. It paid no cash dividend for 2025. 전성우 and related parties held 36.00% at year end.

From the 2025 annual report

Staff: 77 (42 men, 35 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.5B. Directors and auditors: 4, paid ₩524M in total.

No cash dividend was paid for 2025.

Largest shareholder

전성우 holds 26.57%; with 7 related parties the group holds 36.00% of common shares at year end (from 35.98% at the start of the year).

Auditor: 동현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary